Gribero (Dabigatran Etexilate)

Gribero is indicated for several thromboembolic conditions where anticoagulation is required.

• Prevention of stroke and systemic embolism in patients with non‑valvular atrial fibrillation.
• Treatment of acute deep vein thrombosis (DVT) and pulmonary embolism (PE).
• Extended secondary prevention of recurrent DVT and PE after initial therapy.
• Use in patients who require an oral anticoagulant alternative to vitamin K antagonists.

The safety profile of Gribero includes both common and less frequent but serious adverse events.

Common

• Dyspepsia or indigestion.
• Minor gastrointestinal bleeding such as epistaxis or gum bleeding.
• Nausea or abdominal discomfort.
• Headache.
• Dizziness or light‑headedness.

Serious

• Major bleeding, including intracranial hemorrhage.
• Gastrointestinal hemorrhage requiring medical attention.
• Allergic reactions such as rash, pruritus, or angioedema.

Before prescribing Gribero, clinicians should evaluate several patient‑specific factors to minimize risk.

• Assess renal function; dose adjustment may be required in impaired clearance.
• Review history of bleeding disorders or recent major surgery.
• Caution in patients with uncontrolled hypertension.
• Evaluate concomitant use of antiplatelet agents or NSAIDs.
• Avoid in patients with active pathological bleeding.
• Consider pregnancy and lactation status; safety data are limited.
• Monitor for signs of thromboembolic events if therapy is interrupted.

Gribero can interact with other medicines, affecting its anticoagulant effect or increasing bleeding risk.

Avoid

• Strong P‑glycoprotein (P‑gp) inhibitors such as ketoconazole, itraconazole, or ritonavir.
• Concurrent use of other anticoagulants (e.g., warfarin, heparin) or antiplatelet drugs (e.g., clopidogrel, aspirin) without careful monitoring.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that increase gastrointestinal bleeding risk.

Use with caution

• Moderate P‑gp inhibitors (e.g., amiodarone, verapamil, quinidine).
• Certain antifungal agents (e.g., fluconazole) and antibiotics (e.g., erythromycin).
• Herbal supplements such as St John’s wort that may alter drug metabolism.
• Patients with hepatic impairment.